Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02286609
Recruitment Status : Completed
First Posted : November 10, 2014
Last Update Posted : August 18, 2017
Sponsor:
Information provided by (Responsible Party):
PTC Therapeutics

Brief Summary:
This is a non-randomized, open-label, single-dose study to compare the PK of 21-desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with moderate hepatic impairment (based on the Child Pugh classification, Grade B) to that of 8 healthy matched control subjects (age, body mass index [BMI], and gender).

Condition or disease Intervention/treatment Phase
Hepatic Impairment Drug: Deflazacort Phase 1

Detailed Description:

This is a non-randomized, open-label, single-dose study to compare the PK of 21-desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with moderate hepatic impairment (based on the Child Pugh classification, Grade B) to that of 8 healthy matched control subjects (age, body mass index [BMI], and gender).

On Day 1, a single oral dose of deflazacort will be administered followed by serial blood sampling for 24 hours to assess the PK of 21-desacetyl-DFZ and, if data permits, deflazacort.

Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Subjects will return to the Clinical Research Unit (CRU) 3 days (± 1 day) following study drug administration to determine if any adverse events (AEs) have occurred since the last study visit. Subjects who terminate the study early will be contacted if the Principal Investigator (PI) deems necessary.

A total of sixteen (16) adult male and female subjects will be enrolled. Hepatic Impaired Cohort: Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale).

Healthy Match Control Cohort: Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Single Dose Evaluation of the Effects of Moderate (Child-Pugh Grade B) Hepatic Impairment on Deflazacort Pharmacokinetics
Study Start Date : December 2014
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Deflazacort

Arm Intervention/treatment
Experimental: Hepatic Impairment
Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
Drug: Deflazacort
Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
Other Name: DFZ

Experimental: Healthy Volunteer
Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
Drug: Deflazacort
Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
Other Name: DFZ




Primary Outcome Measures :
  1. Hepatic impairment on the pharmacokinetics (PK) of deflazacort in subjects with moderate hepatic impairment including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration. [ Time Frame: 1 day ]
    Hepatic impairment on the pharmacokinetics (PK) of deflazacort in subjects with moderate hepatic impairment including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration.


Secondary Outcome Measures :
  1. Safety and tolerability of one dose of deflazacort in subjects with hepatic impairment as measured by capturing occurrence of adverse events. [ Time Frame: 1 day ]
    Safety and tolerability of one dose of deflazacort in subjects with hepatic impairment as measured by capturing occurrence of adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All Subjects

  • Continuous non-smokers or moderate smokers.
  • For a female of non-childbearing potential: must have undergone one a sterilization procedures or be postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum levels consistent with postmenopausal status
  • A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days
  • If male, must agree not to donate sperm from dosing until 90 days Subject with Moderate Hepatic Impairment
  • Adult male or female, 18 80 years of age
  • BMI ≥ 18.5 and ≤ 40.0 kg/m2
  • Subject's score on the Child-Pugh scale must range from 7 to 9 (moderate hepatic insufficiency)
  • Subject has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology.

Healthy Subject

- Healthy adult male and female subjects will be matched 1:1 to a specific subject in the moderate hepatic impairment cohort based upon age, BMI, and gender.

Exclusion Criteria:

  • Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study drug, related compounds (e.g., steroids or their formulations including lactose and corn starch).
  • History (within the last year prior to dosing) or presence of peptic ulcers.
  • History or presence of:

    • Gastritis or esophagitis, diverticulitis, ulcerative colitis (if there is probability of impending perforation), abscess or pyogenic infections, or fresh intestinal anastomosis;
    • Previous corticoids-induced myopathy;
    • Ocular herpes simplex;
    • Symptomatic cardiomyopathy at screening;
    • Immunosuppression or other contraindications for corticosteroid treatment;
    • History of chronic systemic fungal or viral infections;
    • Galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption;
    • Osteoporosis;
    • Myasthenia gravis;
    • Epilepsy;
    • Idiopathic hypocalcuria.
  • Seated blood pressure is less than 90/40 mmHg or greater than 160/95 mmHg
  • Seated heart rate is lower than 40 bpm or higher than 99 bpm
  • QTcF interval is > 500 msec
  • Has received any live or live-attenuated vaccine within 30 days
  • Has received any immunosuppressive agents, coal tar, and/or radiation therapies within 30 days
  • Has received injectable corticoids in the 12 weeks prior to dosing or any oral form of corticoids in 30 days
  • Unable to refrain from or anticipates the use of:

    • Any drug known to be moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A or P-glycoprotein (P-gp) for 14 days or 28 days, respectively
    • Any medication or substance, vitamin supplements, natural or herbal supplements which cannot be discontinued at least 14 days
  • Female subjects of childbearing potential.
  • Female subjects who are pregnant or lactating.
  • Positive results at screening for HIV.
  • Has been on a diet incompatible with the on study diet within 28 days
  • Donation of blood or significant blood loss within 56 days
  • Plasma donation within 7 days
  • Participation in another clinical trial within 28 days Subject with Moderate Hepatic Impairment
  • Has history of organ transplant.
  • History of drug abuse within the past 2 years
  • Has a positive urine drug or urine/breath alcohol testing Healthy Subject
  • History or presence of alcoholism or drug abuse within the past 2 years
  • Positive urine drug or urine/breath alcohol testing results at screening or check in.
  • Positive results at screening for HBsAg or HCV.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02286609


Locations
Layout table for location information
United States, Florida
University of Miami Division of Clinical Pharmacology
Miami, Florida, United States, 33136
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
PTC Therapeutics
Investigators
Layout table for investigator information
Study Director: Bioscience Center Marathon Pharmaceuticals, LLC

Layout table for additonal information
Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT02286609     History of Changes
Other Study ID Numbers: MP-104-CL-023
First Posted: November 10, 2014    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Digestive System Diseases
Deflazacort
Anti-Inflammatory Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs